| Notice of Special Interest—Administrative Supplements to Advance Precision Medicine Using the All of Us Research Programs Data- NOT-PM-22-002 |
Supp
|
May 20, 2022 |
July 06, 2022 |
| Transgender People—Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)- PAR-22-186 |
R21
|
May 19, 2022 |
December 08, 2024 |
| Understanding the Clinical History of Bacterial Sexually Transmitted Infections (STI) to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed)- RFA-AI-22-034 |
R01
|
May 12, 2022 |
September 13, 2022 |
| Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)- PAR-22-105 |
R01
|
May 10, 2022 |
May 08, 2025 |
| Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)- PAR-22-109 |
R21
|
May 10, 2022 |
May 08, 2025 |
| Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 Clinical Trial Not Allowed)- RFA-AI-22-037 |
R01
|
May 10, 2022 |
September 15, 2022 |
| Notice of Special Interest (NOSI)—Administrative Supplements for NIAID Regional Biocontainment Laboratories (RBL) and other NIH Grantees Conducting Research at RBL-affiliated Sites- NOT-AI-22-049 |
Supp
|
May 04, 2022 |
June 01, 2022 |
| Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy- NOT-CA-22-063 |
Multiple |
May 03, 2022 |
July 05, 2024 |
| Notice of Special Interest (NOSI)— Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP) - NOT-AI-22-042 |
R01
|
April 29, 2022 |
May 08, 2025 |
| Notice of Special Interest (NOSI)—Towards Developing a Cure for HBV in HIV/HBV Co-Infection - NOT-AI-22-043 |
R01, R41/R42, R21, R43/R44
|
April 29, 2022 |
May 08, 2025 |
| Notice of Special Interest (NOSI)—Administrative Supplements for Lyme Disease and other Tickborne Illnesses - NOT-AI-22-048 |
Supp
|
April 27, 2022 |
May 24, 2022 |
| Limited Interaction Targeted Epidemiology—Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)- RFA-AI-22-024 |
UG3/UH3
|
April 13, 2022 |
August 04, 2022 |
| Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)- RFA-OD-22-008 |
R03
|
April 08, 2022 |
July 02, 2024 |
| NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)- PAR-20-153 |
R25
|
April 08, 2022 |
July 14, 2022 |
| Notice of Special Interest (NOSI)—Administrative Supplements for Research on Womens Health in the IDeA States- NOT-GM-22-005 |
Supp
|
April 06, 2022 |
October 18, 2024 |
| Development and Optimization of Next-Generation Immunological Assays to Support Influenza Clinical Studies and Trials (UH2/UH3 Clinical Trial Not Allowed)- RFA-AI-22-020 |
UH2/UH3
|
April 05, 2022 |
July 02, 2022 |
| Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)- RFA-AI-22-028 |
R01
|
April 05, 2022 |
July 30, 2022 |
| Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)- RFA-OD-22-009 |
R01
|
April 05, 2022 |
July 02, 2024 |
| Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)- RFA-AI-22-025 |
R01
|
March 29, 2022 |
August 04, 2022 |
| NIAID Research Education Program (R25 Clinical Trial Not Allowed)- PAR-22-134 |
R25
|
March 15, 2022 |
October 10, 2024 |
| Limited Competition—Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)- RFA-HL-23-007 |
K38
|
March 14, 2022 |
January 11, 2025 |
| Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)- RFA-AI-22-022 |
R61/R33
|
March 10, 2022 |
August 04, 2022 |
| International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)- PAR-22-118 |
R25
|
March 10, 2022 |
June 07, 2024 |
| Notice of Special Interest (NOSI)— NIAID Administrative Supplement To Promote Discovery of Medical Countermeasures Against Chemical Threats - NOT-AI-22-030 |
Supp
|
March 02, 2022 |
March 02, 2024 |
| Improved Drug Susceptibility Testing (DST) for Tuberculosis (R01 Clinical Trial Not Allowed)- RFA-AI-22-016 |
R01
|
March 02, 2022 |
July 09, 2022 |
